Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 18 and up

Antibiotic Prophylaxis Before Simple Tooth Extraction in Immunosuppressed Patients with Autoimmune Rheumatic Diseases

Official title: Effectiveness of Short-Course Antibiotic Prophylaxis After Simple Tooth Extraction in Immunosuppressed Patients With Autoimmune Rheumatic Diseases

Run by University of Sao Paulo General Hospital · NCT07275580 · Data updated 2026-11-12

This trial tests whether giving a single dose of amoxicillin before a simple tooth extraction can prevent infections in adults with autoimmune rheumatic diseases who are on immunosuppressive therapy.

Quick facts

PhasePhase 4
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment352 (estimated)
SponsorUniversity of Sao Paulo General Hospital
Academic / other
Drugs / interventionsdenosumab, radiation, methotrexate, cyclophosphamide, prednisone
Locations1 site (São Paulo, São Paulo)
StatusRecruiting
StartedOctober 7, 2026
Main results expectedJune 1, 2029
Study endsDecember 30, 2029
Registry record updatedOctober 15, 2026
Trial IDNCT07275580 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (≥18) with an autoimmune rheumatic disease on immunosuppressive therapy who require a simple tooth extraction and have no current infection requiring antibiotics, and who can provide informed consent.

Probably not a fit

Patients not on immunosuppressive therapy, those undergoing complex or multiple extractions, or those with active infections or contraindications to antibiotics may not benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized, double-blind, placebo-controlled Phase 4 trial evaluating the need for antibiotic prophylaxis before simple tooth extractions in adults with autoimmune rheumatic diseases who are immunosuppressed. Participants receive either amoxicillin or placebo prior to extraction, and postoperative infection rates, infection severity, and other complications are monitored. The study also explores how the type of ARD and immunosuppressive treatment may influence infection risk. The trial aims to provide evidence to guide antibiotic stewardship in this specific patient population.

Why it matters

Potential benefit: If successful, the trial could reduce unnecessary antibiotic use and associated risks while maintaining protection against postoperative infections in immunosuppressed ARD patients.

How similar studies have gone: Previous studies in immunocompromised populations suggest antibiotics may not always be necessary for simple extractions, but this is the first prospective, randomized trial focused on ARD patients.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age ≥18 years
* Confirmed diagnosis of an ARD: SLE, RA, JIA, AS, PsA, IIM, systemic vasculitis, primary Sjögren's syndrome, or SSc
* Use of prednisone and/or at least one synthetic immunosuppressant (methotrexate, azathioprine, mycophenolate mofetil, leflunomide, cyclophosphamide, cyclosporine, or tacrolimus), immunobiological agent or immunomodulator (chloroquine, sulfasalazine), with no plans to switch medications.
* Indication for simple tooth extraction with chronic odontogenic focus
* Provided informed consent

Exclusion Criteria:

* Individuals who do not agree to participate in the study will be excluded.
* Patients requiring extractions that are more complex from a technical standpoint, such as impacted third molars.
* Patients with local or systemic conditions requiring more extensive antibiotic coverage, such as cases with clinical signs of acute infections, patients on anticoagulant therapy, patients with heart disease, patients who have undergone radiation therapy, or patients currently being treated for neoplasms;
* Patients allergic to amoxicillin.
* Patients currently receiving any antibiotic prophylaxis or treatment;
* Patients who have undergone corticosteroid pulse therapy within the last month;
* Patients taking drugs with antiresorptive effects on bone, such as oral or injectable bisphosphonates and denosumab.

Where it's running

  • Rheumatology Division, Faculdade de Medicina da USP, São Paulo, SP, São Paulo, Sao paulo 01246-903
    São Paulo, São Paulo, Brazil
    Recruiting

Study contacts

  • Principal investigator: Eloisa Bonfá, Full Professor — Hospital das Clínicas da Faculdade de Medicina da USP - HCFMUSP
  • Study coordinator: Eloisa Bonfá, Full Professor
  • Email: eloisa.bonfa@hc.fm.usp.br
  • Phone: +55 11 30617492

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.